-
1 Comment
Shenzhen Kangtai Biological Products Co., Ltd is currently in a long term downtrend where the price is trading 9.2% below its 200 day moving average.
From a valuation standpoint, the stock is 395.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 47.7.
Shenzhen Kangtai Biological Products Co., Ltd's total revenue sank by 6.2% to $550M since the same quarter in the previous year.
Its net income has increased by 0.5% to $174M since the same quarter in the previous year.
Finally, its free cash flow grew by 129.6% to $200M since the same quarter in the previous year.
Based on the above factors, Shenzhen Kangtai Biological Products Co., Ltd gets an overall score of 2/5.
| Exchange | SHE |
|---|---|
| Sector | Healthcare |
| CurrencyCode | CNY |
| ISIN | CNE100002Q33 |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | 204.14 |
|---|---|
| Target Price | 16.44 |
| Dividend Yield | 0.3% |
| Beta | 0.75 |
| Market Cap | 16B |
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies vaccines (human diploid cell, freeze-dried) for human use; haemophilus influenzae type b conjugate vaccines; measles and rubella combined vaccines (live); SARS-CoV-2 vaccines (vero cell, inactivated); and COVID-19 vaccines (ChAdOx1-S recombinant). It also develops measles, mumps, and rubella vaccines; DTaP-Hib-IPV combined vaccines, 4-valent influenza (split) vaccines, and poliomyelitis vaccines (vero cells, inactivated for the Sabin strain). In addition, the company engages in general and special freight transportation; warehousing services; technology development; import and export of goods and technology; agency import and export; investment in and establishment of pharmaceutical projects and other industries; pharmaceutical technology development, information consulting, and leasing services for self-owned buildings and equipment; wholesale and trade of preventive biological products; technical services; technical consulting and exchange; technology transfer and promotion; and contract manufacturing of pharmaceutical products. It exports its products. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300601.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
